Pila Pharma H1 FY26 EBIT loss narrows to SEK 3.85 million; net loss improves to SEK 3.87 million
Reuters2026/08/27 06:33- Pila Pharma posted an operating loss of SEK 3.85 million for H1 2026, narrowing from SEK 4.09 million a year earlier.
- Net loss totaled SEK 3.87 million, improving from SEK 4.1 million; loss per share narrowed to SEK 0.08 from SEK 0.15.
- Cash flow was SEK -17.97 million, compared with SEK -3.81 million, while cash stood at SEK 3.26 million at June 30.
- Equity rose to SEK 16.11 million, lifting the solvency ratio to 96% from 33%.
- Regulatory clearance was secured to run the 12-week PP-CT04 obesity trial of XEN-D0501; CEO Gustav H. Gram flagged higher-dose testing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lazard paper warns global supply chains face O-ring-style single-point failures amid geopolitics
Andalan Perkasa Abadi says unaware of material information behind NASA share volatility
Massive Buyback Faces "Cold Reception"! U.S. Treasury Bond Purchase Plan Hits a Wall, Liquidity Tool Risks Becoming Ineffective
The US Treasury's expanded repo operations faced a record-low subscription ratio, highlighting a bottleneck in long-term bond market absorption, which may force officials to further cut issuance of the less liquid 20-year US Treasury bonds.
Crypto prices
More
